Health

D2G Oncology

Private Company

D2G Oncology leverages quantitative and multiplexed functional cancer genomics to relate drugs to genotypes to transform precision cancer therapeutics.

d2g-oncology.com

U.S.

Therapeutics

Leaders
Jonathan MacQuitty, Ph.D.

CEO

Monte Winslow, Ph.D.

Cofounder

Dmitri Petrov, Ph.D.

cofounder

Ian Winters, Ph.D.

cofounder

D2G Oncology leverages quantitative and multiplexed functional cancer genomics to relate drugs to genotypes to transform precision cancer therapeutics.